When Roman Gubler was a healthy 9-year-old boy in Oshawa, Ontario, he never imagined his story would end up in a scientific journal. But after being diagnosed with lymphoma last spring and successfully treated at The Hospital for Sick Children in Toronto, Roman's family volunteered his tumor samples for research. Now, scientists say his contribution and that of hundreds of other young patients could help save lives for generations to come.
A new international study published in Nature reveals that common chemotherapy leaves detectable DNA "fingerprints" in childhood tumors. Researchers at SickKids, along with partners in Australia and the United States, analyzed more than 600 tumors from 544 young patients. Using whole-genome sequencing and powerful computer programs, they discovered that chemotherapy leaves distinct marks on cancer DNA — like clues left behind at a crime scene.
The findings surprised the research team. "There's a long-standing belief that pediatric cancers are genetically quiet because they haven't had much time to mutate," said Dr. Adam Shlien, the study's lead author and a senior scientist at SickKids. "Instead, it was mind-blowing to see how many mutations found in tumors that had relapsed or spread were linked to the chemotherapy used to treat the cancer in the first place."
Some of these DNA fingerprints appeared just 91 days after treatment began. For one common type of chemotherapy called platinum-based drugs — used in nearly half of all treated cancer patients — 48 percent of tumors showed detectable damage within just 18 months. This matters because when doctors can spot these changes early, they might catch treatment resistance before the cancer grows back or spreads.
The discovery comes at a hopeful time for childhood cancer. More than 85 percent of young patients now survive, thanks to decades of research. But chemotherapy can damage healthy cells too, sometimes causing heart problems or new cancers decades later. For a child who has their whole life ahead of them, these "late effects" can mean facing a new health crisis in their teens or twenties.
"Developing a secondary cancer or cardiac issue a decade later means confronting a new, life-altering crisis in their teens or twenties," said Dr. Mehdi Layeghifard, the study's first author. Now that researchers have mapped these DNA fingerprints, doctors may one day use them to monitor patients and adjust treatment before resistance develops.
The team spent years developing new computer methods to detect these subtle patterns. Dr. Shlien believes this is the largest study of its kind ever conducted. Families like the Gublers made it possible — the majority of participants joined through SickKids' Kids Cancer Sequencing program, voluntarily sharing their data to help other children.
"If my little 9-year-old boy can be part of such important research, then that's pretty wonderful," said Nicole Gubler, Roman's mother.